抑癌基因 EZH2 在乳腺癌中的非典型功能。
Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
机构信息
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
出版信息
Am J Pathol. 2021 May;191(5):774-783. doi: 10.1016/j.ajpath.2021.01.013. Epub 2021 Feb 6.
Abstract
Enhancer of Zeste Homologue 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) that is critical for determining cell identity. An epigenetic writer, EZH2 has a well-defined role in transcriptional repression by depositing trimethyl marks on lysine 27 of histone H3. However, there is mounting evidence that histone methyltransferases like EZH2 exert histone methyltransferase-independent functions. The relevance of these functions to breast cancer progression and their regulatory mechanisms are only beginning to become understood. Here, we review the current understanding of EZH2 H3K27me3-independent, noncanonical, functions and their regulation in breast cancer.
摘要
增强子结合锌指蛋白 2（EZH2）是多梳抑制复合物 2（PRC2）的催化亚基，对于确定细胞身份至关重要。EZH2 作为一种表观遗传写入器，通过在组蛋白 H3 的赖氨酸 27 上沉积三甲基标记，在转录抑制中发挥着明确的作用。然而，越来越多的证据表明，EZH2 等组蛋白甲基转移酶发挥着组蛋白甲基转移酶非依赖性的功能。这些功能与乳腺癌进展的相关性及其调控机制才刚刚开始被理解。在这里，我们综述了目前对 EZH2 H3K27me3 非依赖性、非典型功能及其在乳腺癌中的调控的认识。
相似文献
1
Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.抑癌基因 EZH2 在乳腺癌中的非典型功能。
Am J Pathol. 2021 May;191(5):774-783. doi: 10.1016/j.ajpath.2021.01.013. Epub 2021 Feb 6.
2
The noncanonical role of EZH2 in cancer.EZH2 在癌症中的非典型作用。
Cancer Sci. 2021 Apr;112(4):1376-1382. doi: 10.1111/cas.14840. Epub 2021 Feb 24.
3
Regulation of histone methylation by automethylation of PRC2.PRC2 的自身甲基化对组蛋白甲基化的调控。
Genes Dev. 2019 Oct 1;33(19-20):1416-1427. doi: 10.1101/gad.328849.119. Epub 2019 Sep 5.
4
Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.多梳蛋白复合物的结构组装与 EZH2 在癌症进展中的作用：综述。
J Cancer Res Ther. 2021 Apr-Jun;17(2):311-326. doi: 10.4103/jcrt.JCRT_1090_19.
5
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.通过 EZH2 降解剂解析和靶向多发性骨髓瘤中非典型 EZH2 功能。
Oncogene. 2023 Mar;42(13):994-1009. doi: 10.1038/s41388-023-02618-5. Epub 2023 Feb 7.
6
EZH2 methyltransferase and H3K27 methylation in breast cancer.EZH2 甲基转移酶和 H3K27 甲基化在乳腺癌中的作用。
Int J Biol Sci. 2012;8(1):59-65. doi: 10.7150/ijbs.8.59. Epub 2011 Nov 18.
7
EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.EZH1介导组蛋白H3赖氨酸27的甲基化，并在维持干细胞特性和执行多能性方面补充EZH2的功能。
Mol Cell. 2008 Nov 21;32(4):491-502. doi: 10.1016/j.molcel.2008.10.016.
8
Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.SMYD2 介导的赖氨酸甲基化调控 EZH2 参与肿瘤发生。
Cell Rep. 2019 Nov 5;29(6):1482-1498.e4. doi: 10.1016/j.celrep.2019.10.004.
9
Polycomb Repressive Complex 2 in Oncology.多梳抑制复合物 2 在肿瘤学中的作用。
Cancer Treat Res. 2023;190:273-320. doi: 10.1007/978-3-031-45654-1_9.
10
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.EZH2介导的H3K27me3参与人类癌症中肝癌缺失基因1的表观遗传抑制。
PLoS One. 2013 Jun 27;8(6):e68226. doi: 10.1371/journal.pone.0068226. Print 2013.
引用本文的文献
1
Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment.EZH2对FADS2的差异调节揭示了卵巢癌治疗中的代谢脆弱性。
EBioMedicine. 2025 Aug 15;119:105879. doi: 10.1016/j.ebiom.2025.105879.
2
BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling.BRD9作为一种甲基精氨酸阅读器发挥作用，以调节AKT-EZH2信号传导。
Sci Adv. 2025 Apr 25;11(17):eads6385. doi: 10.1126/sciadv.ads6385.
3
Expression patterns of H3K27me3 for differentiation of breast fibroadenomas and phyllodes tumors.H3K27me3在乳腺纤维腺瘤和叶状肿瘤分化中的表达模式。
APMIS. 2025 Jan;133(1):e13485. doi: 10.1111/apm.13485. Epub 2024 Oct 25.
4
RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-mediated WNT7B/β-catenin Pathway.RBM39通过EZH2介导的WNT7B/β-连环蛋白信号通路促进胆管癌生长。
Cell Mol Gastroenterol Hepatol. 2025;19(1):101404. doi: 10.1016/j.jcmgh.2024.101404. Epub 2024 Sep 14.
5
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression.超深度 RNA-seq 的综合分析揭示了在前列腺癌进展过程中，作为激活致癌程序的一种机制，存在着不同的启动子使用。
Nat Cell Biol. 2024 Jul;26(7):1176-1186. doi: 10.1038/s41556-024-01438-3. Epub 2024 Jun 13.
6
Genetic analysis of PALB2 gene WD40 domain in canine mammary tumour patients.犬乳腺肿瘤患者 PALB2 基因 WD40 结构域的遗传分析。
Vet Med Sci. 2024 May;10(3):e1366. doi: 10.1002/vms3.1366.
7
Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.发现一种新型强效 EZH2 PROTAC 降解剂，可靶向 EZH2 的非典型致癌功能。
Eur J Med Chem. 2024 Mar 5;267:116154. doi: 10.1016/j.ejmech.2024.116154. Epub 2024 Jan 26.
8
Polycomb Repressive Complex 2 in Oncology.多梳抑制复合物 2 在肿瘤学中的作用。
Cancer Treat Res. 2023;190:273-320. doi: 10.1007/978-3-031-45654-1_9.
9
Non-canonical functions of EZH2 in cancer.EZH2在癌症中的非经典功能。
Front Oncol. 2023 Aug 18;13:1233953. doi: 10.3389/fonc.2023.1233953. eCollection 2023.
10
An EZH2-NF-κB regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer.EZH2-NF-κB调控轴驱动三阴性乳腺癌中促癌基因特征的表达。
iScience. 2023 Jun 14;26(7):107115. doi: 10.1016/j.isci.2023.107115. eCollection 2023 Jul 21.
本文引用的文献
1
Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.EZH2 在 T367 位点磷酸化的亚细胞定位使化生性乳腺癌亚型分层。
Breast Cancer. 2021 Mar;28(2):496-505. doi: 10.1007/s12282-020-01189-7. Epub 2020 Nov 27.
2
Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase ε.基底样乳腺癌中 CDK2 的过度激活导致基因组完整性缺陷，可通过靶向 DNA 聚合酶 ε 加以利用。
Mol Cell. 2020 Nov 19;80(4):682-698.e7. doi: 10.1016/j.molcel.2020.10.016. Epub 2020 Nov 4.
3
EZH2-Targeted Therapies in Cancer: Hype or a Reality.EZH2 靶向治疗在癌症中的应用：炒作还是现实？
Cancer Res. 2020 Dec 15;80(24):5449-5458. doi: 10.1158/0008-5472.CAN-20-2147. Epub 2020 Sep 25.
4
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis.PRMT1 介导的 EZH2 甲基化调控其稳定性并促进乳腺癌转移。
Cell Death Differ. 2020 Dec;27(12):3226-3242. doi: 10.1038/s41418-020-00615-9. Epub 2020 Sep 7.
5
A partially disordered region connects gene repression and activation functions of EZH2.部分无序区域连接 EZH2 的基因抑制和激活功能。
Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):16992-17002. doi: 10.1073/pnas.1914866117. Epub 2020 Jul 6.
6
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.EZH2 催化活性抑制选择性靶向三阴性乳腺癌的转移亚群。
Cell Rep. 2020 Jan 21;30(3):755-770.e6. doi: 10.1016/j.celrep.2019.12.056.
7
Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.使用靶向EED的双价化学降解剂降解多梳抑制复合物2
Cell Chem Biol. 2020 Jan 16;27(1):47-56.e15. doi: 10.1016/j.chembiol.2019.11.006. Epub 2019 Dec 9.
8
Discovery of a first-in-class EZH2 selective degrader.发现首个 EZH2 选择性降解剂。
Nat Chem Biol. 2020 Feb;16(2):214-222. doi: 10.1038/s41589-019-0421-4. Epub 2019 Dec 9.
9
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.EED 靶向 PROTACs 降解 PRC2 复合物中的 EED、EZH2 和 SUZ12。
Cell Chem Biol. 2020 Jan 16;27(1):41-46.e17. doi: 10.1016/j.chembiol.2019.11.004. Epub 2019 Nov 27.
10
Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.SMYD2 介导的赖氨酸甲基化调控 EZH2 参与肿瘤发生。
Cell Rep. 2019 Nov 5;29(6):1482-1498.e4. doi: 10.1016/j.celrep.2019.10.004.
Zotero 插件